CRIS Current Research Information System

AUTERI, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.341
NA - Nord America 1.854
EU - Europa 1.271
AF - Africa 151
SA - Sud America 117
OC - Oceania 5
Totale 5.739
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.807
SG - Singapore 648
CN - Cina 595
VN - Vietnam 575
IT - Italia 316
DE - Germania 191
SE - Svezia 165
GB - Regno Unito 156
HK - Hong Kong 138
IN - India 122
FR - Francia 88
BR - Brasile 79
KR - Corea 75
RU - Federazione Russa 63
IE - Irlanda 62
FI - Finlandia 57
NL - Olanda 56
CI - Costa d'Avorio 54
JP - Giappone 35
TG - Togo 35
CA - Canada 30
ZA - Sudafrica 22
PH - Filippine 20
TH - Thailandia 19
ID - Indonesia 18
JO - Giordania 17
BE - Belgio 16
TW - Taiwan 16
PL - Polonia 15
BG - Bulgaria 14
BD - Bangladesh 12
CH - Svizzera 12
MX - Messico 12
TR - Turchia 11
AR - Argentina 10
AT - Austria 10
NG - Nigeria 10
EE - Estonia 9
PK - Pakistan 9
UA - Ucraina 9
EC - Ecuador 8
CZ - Repubblica Ceca 7
CO - Colombia 6
PY - Paraguay 6
IQ - Iraq 5
LV - Lettonia 5
MA - Marocco 5
SC - Seychelles 5
AU - Australia 4
EG - Egitto 4
ES - Italia 4
ET - Etiopia 4
IR - Iran 4
LT - Lituania 4
TN - Tunisia 4
AZ - Azerbaigian 3
MY - Malesia 3
PE - Perù 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
CL - Cile 2
CY - Cipro 2
DK - Danimarca 2
DZ - Algeria 2
HR - Croazia 2
JM - Giamaica 2
RO - Romania 2
UY - Uruguay 2
AO - Angola 1
BB - Barbados 1
CG - Congo 1
CR - Costa Rica 1
GA - Gabon 1
GE - Georgia 1
GF - Guiana Francese 1
GR - Grecia 1
HU - Ungheria 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
MG - Madagascar 1
MK - Macedonia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
RS - Serbia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 5.739
Salva come PNG Salva come JPEG
Città #
Singapore 477
Ashburn 278
Chandler 197
San Jose 149
Hanoi 135
Hefei 130
Hong Kong 128
Ho Chi Minh City 121
Southend 110
Dong Ket 93
Santa Clara 81
Fairfield 69
Beijing 68
Dallas 65
Seoul 63
Dublin 62
Bologna 59
Abidjan 54
Princeton 52
Los Angeles 49
Milan 45
Boardman 42
Helsinki 41
Council Bluffs 38
Houston 36
Lomé 35
Hyderabad 34
Munich 34
Cornaredo 32
New York 32
Seattle 32
Lauterbourg 30
Wilmington 30
Woodbridge 29
Redmond 26
Tokyo 24
Cambridge 23
Ann Arbor 22
Turin 21
Bremen 19
Buffalo 19
Nanjing 19
Amman 17
Da Nang 17
Haiphong 17
Brussels 16
Frankfurt am Main 16
Shanghai 15
Berlin 14
Sofia 14
Westminster 14
Bengaluru 13
Jakarta 13
Johannesburg 13
Nuremberg 13
Warsaw 12
Lappeenranta 11
Toronto 11
Chicago 10
Rome 10
São Paulo 10
Boydton 9
London 9
Monheim 9
Montreal 9
Phoenix 9
Redondo Beach 9
Amsterdam 8
Bern 8
Des Moines 8
Abeokuta 7
Paris 7
Perugia 7
Shijiazhuang 7
Bình Phước 6
Can Tho 6
Changsha 6
Falkenstein 6
Guangzhou 6
Medford 6
Modena 6
Orem 6
Saint Petersburg 6
San Francisco 6
Shenyang 6
Stockholm 6
Biên Hòa 5
Brno 5
Casalecchio di Reno 5
City of London 5
Fremont 5
Hangzhou 5
Hải Dương 5
Norwalk 5
Qingdao 5
Riga 5
Tongling 5
Turku 5
Vienna 5
Zhengzhou 5
Totale 3.607
Salva come PNG Salva come JPEG
Nome #
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 226
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 220
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 213
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 212
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 209
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 204
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 200
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 197
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 197
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 192
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 192
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 184
Sustained response off therapy after fostamatinib: A chronic refractory ITP case report 156
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 154
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 154
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 151
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 151
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 143
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 142
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 138
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 135
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 134
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 133
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 131
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 127
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 127
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 124
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia 117
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 116
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 106
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study 106
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 104
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms 100
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 96
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 93
Liver and spleen shear-wave elastography in the diagnosis and severity staging of myeloproliferative diseases and myelofibrosis 91
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity 89
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 86
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 83
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 83
null 68
Totale 5.884
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.563
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.563
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021135 0 0 0 0 0 0 0 0 0 3 8 124
2021/2022546 8 17 24 51 32 22 11 49 19 53 155 105
2022/2023760 56 100 45 104 62 78 15 46 137 28 57 32
2023/2024316 16 49 23 32 20 45 2 30 13 30 31 25
2024/20251.169 90 95 89 92 118 65 79 83 51 92 85 230
2025/20262.492 247 248 245 212 252 123 252 141 596 176 0 0
Totale 5.884